Related Experiment Video
Updated: May 19, 2026
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier (MSC) for Lung Cancer Screening
Published on: October 26, 2017
Plasma MicroRNA-21 concentration may be a useful biomarker in glioblastoma patients
Aysegül Ilhan-Mutlu1, Ludwig Wagner, Adelheid Wöhrer
1Department of Medicine, Comprehensive Cancer Center-Central Nervous System Tumours Unit (CCC-CNS), Medical University of Vienna, Vienna, Austria.
Background:
MicroRNAs are proposed as plasma biomarkers in cancer. Glioblastoma is the most frequent primary brain tumor of adults. MicroRNA-21 was shown to induce glioblastoma growth.
Aims:
To evaluate the circulating microRNA-21 in glioblastoma patients.
Methods:
MicroRNA-21 copies in glioblastoma plasma (n = 10, before surgery and during/after concomitant chemoradiotherapy), control plasma (n = 10), and tissue samples were analyzed using RT-qPCR.
Results:
MicroRNA-21 in glioblastoma was significantly higher than controls (p = .02) and decreased significantly in 9 patients (p = .05). One patient with increasing microRNA-21 developed a histopathologically proven recurrence after the second sample collection.
Discussion:
Circulating microRNA-21 might be a useful biomarker in glioblastoma.
More Related Videos
09:33Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
Published on: March 20, 2026
09:40Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
Published on: October 4, 2019